Category: Pleural Mesothelioma

Stereotactic Body Radiation Therapy (SBRT) technology, used in the treatment of non-small cell lung cancer and mesothelioma, will be highlighted at the American Society for Radiation Oncology (ASTRO) conference to be held October 31-November 4 in San Diego.  ASTRO has accepted four abstracts from users of Elekta SBRT technology for the treatment of non-small cell …

Source: : Multimodality Therapy for Malignant Pleural Mesothelioma: Pleurectomy/Decortication Followed by Chemotherapy With Cisplatin/Pemetrexed and Radiotherapy. Abstract 151PD One of the great questions in contemporary mesothelioma treatment is whether pleurectomy/decortication or extrapleural pneumonectomy is the more effective surgical arm for patients with malignant mesothelioma. Different surgeons hold conflicting opinions on this question, but definitive guidance …

Source: Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma Morphotek has announced the beginning of a phase II clinical trial investigating the efficacy of the monoclonal antibody MORAb-009 for the treatment of mesothelioma. The study will evaluate progression-free survival in patients with advanced pleural mesothelioma who are being …

Source: NIH News The development of targeted anti-cancer medications is one of the most important areas of contemporary cancer research. Physicians hope creating agents that are able to select specific cells types over others will lead to treatments that are both more effective and that exhibit less severe side effects. This is especially important for …

Source: Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma Most patients with malignant mesothelioma are only diagnosed with the disease in its later stages, when treatment options are generally limited to systemic chemotherapy. For these patients, combination therapy with pemetrexed and cisplatin is the …

Article: Surgery for Malignant Pleural Mesothelioma Malignant mesothelioma is one of the most difficult diseases in all of medicine to manage effectively. Median survival time typically averages only 12-14 months. For patients lucky enough to receive a diagnosis in the disease’s earliest stages, median survival can sometimes be extended two or three years, but a …

Combination therapy with pemetrexed and cisplatin has been the standard of care for the treatment of mesothelioma since its approval in 2004 by the US FDA. The treatment’s approval was driven by the results of a large Phase III study that demonstrated greater treatment efficacy for patients with malignant mesothelioma than any other chemotherapy treatment …

Source: The Journal of Thoracic and Cardiovascular Surgery Full Title: The Impact of Lymph Node Station on Survival in 348 Patients with Surgically Resected Malignant Pleural Mesothelioma: Implications for Revision of the American Joint Committee on Cancer Staging System The current system for staging cases of pleural mesothelioma is based on a TNM model, where …

Source: Cancer Even as improvements in the therapies available for mesothelioma patients have been made in recent years, the disease remains without cure. Most patients are ineligible for curative surgeries, so investigations into improving the efficacy of chemotherapy are among the most common research programs in contemporary mesothelioma treatment studies. Combination chemotherapy using pemetrexed and …

Source: Environmental Health Perspectives Researchers have identified a number of factors in a patient’s presentation with mesothelioma that serve as important indicators of the disease’s treatability and overall prognosis. Two of the most significant indicators are the gender of the patient and the histological subtype of the disease. In terms of gender, studies have shown …